Global Autologous Cell Therapy Market Size (2024-2030)

The Global Autologous Cell Therapy Market was valued at USD 10.56 billion and is estimated to reach USD 32.27 billion by the conclusion of 2030. The market is projected to exhibit a CAGR of 9% during the forecast period from 2024 to 2030. The primary drivers for this growth include the escalating prevalence of cardiovascular diseases and the increasing incidence of autoimmune disorders.

Industry Overview:

Autologous cell therapy (ACT) represents an innovative medical approach within the field of medicine. This contemporary methodology employs the patient's own cells to address their specific medical conditions. Also known as cellular therapy, autologous cell therapy involves introducing cell components into the patient's body to enhance therapeutic outcomes while mitigating adverse effects. Various types of cells such as T cells, stem cells, fibroblasts, dendritic cells, chondrocytes, among others, are utilized in the process of cellular therapy.

In this treatment modality, cells are harvested from a donor, cultured externally, and subsequently reintroduced into the recipient's body. This approach reduces the risks associated with immune system responses and bio-incompatibility, and has even been instrumental in skin regeneration through bioengineering techniques. Furthermore, it proves beneficial in treating burns, facilitating postoperative recovery, and addressing pressure ulcers. The absence of disease transmission risks associated with non-person-derived cells or grafts further enhances its advantages. In comparison to contemporary transplant methods like xenotransplants and allogeneic transplants, autologous cell therapy is considered a safer and more robust treatment option.

The principal factors fostering the growth of the autologous cell therapy market include the rising incidence of chronic conditions such as autoimmune diseases, cancer, blood disorders, among others. The increasing population affected by chronic illnesses is also contributing significantly to the market expansion.

COVID-19 Impact on the Autologous Cell Therapy Market

COVID-19, an infectious disease that originated in Wuhan, China, has had a substantial impact on global health systems. The highly contagious illness, caused by the severe acute respiratory syndrome coronavirus two (SARS-CoV-2), has spread to numerous countries worldwide since its outbreak in December 2019. The World Health Organization declared it a public health emergency on March 11, 2020.

In response to the COVID-19 pandemic, governmental bodies, research institutions, and numerous biotech and pharmaceutical firms have prioritized the development of rapid and effective technologies for diagnosing the virus. Additionally, the increasing clinical trials exploring the use of autologous cell therapies for COVID-19 treatment are expected to bolster market growth. For instance, a clinical study conducted from January 2020 to March 2021 analyzed the population of Swedish citizens treated with autologous hematopoietic stem cell transplantation for COVID-19 positive patients. Positive outcomes from such studies may lead to the development of novel COVID-19 therapies, thereby fueling market growth.

Market Drivers:

The escalating prevalence of cardiovascular diseases and the rising occurrence of autoimmune disorders are the primary drivers propelling market growth.

The rising incidence of cardiovascular diseases is a significant factor contributing to the expansion of the autologous cell therapy market. Factors such as unhealthy diets, tobacco use, and physical inactivity elevate blood pressure and glucose levels, leading to overweight and obesity. Similarly, the increasing prevalence of autoimmune disorders is driving the growth of the autologous cell therapy market. Autoimmune diseases involve the body's immune system attacking healthy cells, organs, and tissues, thereby impairing bodily functions and potentially posing life-threatening consequences.

Market Restraints:

Insufficient funding and the high costs associated with treatment are hindering market growth.

Several factors are poised to impede the progress of the autologous cell therapy market, including inadequate funding and the substantial costs linked to disease treatment. Governmental restrictions on research and development activities also serve as a restraint on market growth.

Autologous Cell Therapy Market - By Source:

• Bone Marrow
• Epidermis
• Others

In terms of Source, the segment concerning Bone Marrow is anticipated to observe the most favorable Compound Annual Growth Rate (CAGR) throughout the projected period. A bone marrow transplant entails the replacement of damaged and impaired cells with new stem cells within the bone marrow. Due to its potential benefits for individuals with various types of malignant and benign ailments, bone marrow is frequently utilized for autologous cell therapy, thereby propelling market growth throughout the forecasted period.

Autologous Cell Therapy Market - By Application:

• Neurology
• Cancer
• Orthopedic
• Wound Healing
• Cardiovascular
• Immune
• Others

Regarding Applications, the Neurology segment is forecasted to experience the most promising Compound Annual Growth Rate (CAGR) during the projected period. Moreover, the Cancer sector is also expected to exhibit significant growth rates during the forecast period. The surge in the prevalence of neurological disorders, cancer, and autoimmune conditions contributes to the advancement of this market over the forecasted period.

Autologous Cell Therapy Market - By End-User:

• Hospitals
• Research centers
• Ambulatory centers

In terms of End-Users, the category of research utilization dominated the Autologous Cell Therapy Market in 2023 and was predicted to generate the highest revenue. The majority of stem cells are utilized in research endeavors, leading to a substantial revenue share for the research-use segment within the industry. It is anticipated to maintain its dominant position from 2023 to 2028. The potential of cell-based remedies to replace, repair, restore, or regenerate damaged tissues, cells, and organs in the near future is significant. To develop such high-quality and safe treatments as an alternative to conventional treatment methods, researchers are investing substantial amounts into the research and development process.

Autologous Cell Therapy Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East
• Africa

From a geographical perspective, North America is projected to hold the largest market share in 2023, as per estimations. This is attributed to the significant presence of facilities and institutions engaged in research and development within the field of stem cell therapy in the region. Five out of the eight major stem cell research universities globally are situated in the United States, including the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University, the Harvard Stem Cell Institute at Harvard University, the Yale Stem Cell Center, and the Institute for Stem Cell Biology and Regenerative Medicine at Yale University.

The Asia Pacific region is expected to witness a rapid rise in the market for autologous cell therapy, leading to substantial revenue generation. Increased investments by developers and consumers in understanding modern medical therapies are projected to boost the revenues generated by the emerging economies in this region. Various stem cell consortiums are operational in Asian countries, aiming to ensure coordinated and focused research and development initiatives. Additionally, individuals from Western nations have been observed migrating to Asian countries for treatment, potentially due to the countries' more flexible legislative frameworks.

Autologous Cell Therapy Market Share by Company

1. Pharmicell Co. Inc.
2. Vericel Corporation
3. Castle Creek Biosciences Inc.
4. Lineage Cell Therapeutics Inc.
5. BrainStorm Cell Therapeutics
6. Regeneus Ltd.
7. Caladrius Biosciences Inc
8. Opexa Therapeutics Inc
9. U.S. Stem Cell Inc
10. Takeda Pharmaceutical Company Limited.

and other entities play pivotal roles in the market. The industry's mergers and acquisitions have enabled players to diversify and enhance their service offerings.

Recently, American Gene Technologies (AGT) submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for AGT103-T in the treatment of HIV patients.

KEY DEVELOPMENTS IN THE GLOBAL AUTOLOGOUS CELL THERAPY MARKET IN RECENT TIMES:

Product Launch - In April 2022, Aspen Neuroscience, Inc., initiated the first-ever patient screening study of its kind, collaborating with multiple clinical screening sites in the United States.